Summary
The efficacy and tolerability of controlled-release metoprolol (metoprolol CR/ZOK), 100–200 mg, and atenolol, 50–100 mg, once daily was compared in Chinese patients with mild to moderate essential hypertension. The study was of a randomized, double-blind, two-way crossover design. The active treatment periods lasted 4 weeks each and were preceded by a 4-week placebo run-in period. The two double-blind phases were separated by a 2-week washout period on placebo. Blood pressures and heart rates were measured at rest in each 2-week visit and during exercise at the end of each treatment period. Twenty-four patients (M/F=14/10) were valid for efficacy analysis. Their ages ranged from 39 to 68, with a mean of 53.5 years. The rest supine blood pressure and heart rate before active treatment was 160±15/106±6 mmHg and 75±14 beats/min (mean±SD), respectively. A responder was defined as exhibiting a supine diastolic blood pressure ≤90 mmHg or a supine diastolic blood pressure reduction of at least 10% of the baseline level. Both agents had high response rate: 88% and 92% of all patients responded to metoprolol CR/ZOK and atenolol, respectively. Both active treatments considerably reduced resting systolic and diastolic blood pressures and heart rates as compared with baseline (p<0.001), respectively. With controlled-release metoprolol, a more pronounced β1 blockade was obtained than with atenolol, which was expressed as a significant reduction in exercise-induced heart rate at the highest comparable workload compared with placebo (p<0.05). These findings are compatible with those reported from western populations.
Similar content being viewed by others
References
Yusuf S, Pefo R, Levis J, Collins R, Sleight L. Beta blockade during and after myocardial infarction: An overview of the randomized trials.Prog Cardiovasc Dis 1985;17:335–371.
Morgan TO, Sabto J, Anavekar SN, Louis WJ, Doyle AE. A comparison of beta-adrenergic blocking drugs in the treatment of hypertension.Postgrad Med J 1974;50:253–259.
Sandberg A, Ragnarsson G, Johnson UE, Sjogren J: Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR.Eur J Clin Pharmacol 1988;33:S3-S7.
Blomqvist I, Westergren G, Sandberg A, Jonsson UE, Lundborg P. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.Eur J Clin Pharmacol 1988;33:S19-S24.
Sandberg A, Blomqvist I, Jonsson, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol; A comparison with conventional tablets.Eur J Clin Pharmacol 1988;33:S9-S14.
Lee YT, Liau CS, Wong ECK, Chen WJ, Chen MF, Chen CC. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol in healthy Chinese subjects.Cardiovasc Drugs Ther 1989;3:529–533.
Darmansjah I, Wong ECK, Setiawati A, Moeloek D, Irawati D. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: A comparison with conventional formulations and atenolol.J Clin Pharmacol 1990;30:S39-S45.
Dimenas E, Ostergren J, Lindvall K, Dahlof C, Westergren G, de Faire U. Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol.J Clin Pharmacol 1990;30:S82-S90.
Ryden L, Kristensson BE, Westergren G. Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: A comparison with conventional tablets.Eur J Clin Pharmacol 1988;33:S33-S37.
Bruce R, Kusumi F, Hosmer D: Maximal oxygen intake and normographic assessment of functional aerobic impairment in cardiovascular disease.Am Heart J 1973;85:546–562.
Patrick J, Bassey J, Morrant J, Macdonald I: Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years.J Clin Pharmacol 1990;30:S108-S116.
Dimenas E, Dahlof C, Heibel B, et al. Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects—a comparison with atenolol.Eur J Clin Pharmacol 1990;38:571–578.
Walle PO, Westergren G, Dimenas O, Albrektsen T. The effects of 100 mg doses of metoprolol CR and atenolol on blood pressure and well-being. Abstract from XXth International Congress of Internal Medicine, Stockholm, Sweden 1990.
Klein G, Berger J, Olsson G, Menzel T. A double blind comparison of metoprolol CR/ZOK 50 mg once daily for uncomplicated hypertension.J Clin Pharmacol 1990;30:S72-S77.
Lofdahl C, Dahlof C, Westergren G, Olofsson B. Controlled-release metoprolol compared to atenolol in asthmatic patients: Interaction with terbutaline.Eur J Clin Pharmacol 1988;33:S25-S32.
Houtzagens J, Smilde J, Creytens G, Westergren G. Efficacy and tolerability of a new controlled-release formulation of metoprolol: A comparison with conventional tablets.Eur J Clin Pharmacol 1988;33:S39-S44.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, MF., Yang, CY., Chen, WJ. et al. A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. Cardiovasc Drug Ther 9, 401–406 (1995). https://doi.org/10.1007/BF00879028
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879028